EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas

Alan H Siegel iD, Andrea Baldwin, Kara Heisey, Kailey Herrera, Anne Dufek, Hemaxi Patel, AeRang Kim, Miriam Bornhorst iD, Brian D Weiss iD, Peter de Blank, Michael J Fisher, Brigitte C Widemann und 1 weitere

Pediatric Blood & Cancer · 2026-09 · 73 (9)

DOI: 10.1002/1545-5017.70477 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 29.07.2026. Verfasst von Alan H Siegel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Benzimidazoles, Neurofibroma, Plexiform, Neurofibromatosis 1, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selumetinib, a mitogen‐activated protein kinase kinase inhibitor, was the first Food and Drug Administration‐approved treatment for children with neurofibromatosis type 1‐associated inoperable plexiform neurofibromas. We evaluated hematologic effects in 98 pediatric participants from the SPRINT Phase 1/2 trial (NCT01362803) with a median follow‐up of 5.1 years (range: 0.2–11 years). Over 90% of values for white blood cell count, platelet count, absolute neutrophil count, and absolute lymphocyte count remained within normal limits across timepoints. There was a statistically significant, but unlikely clinically significant, decrease in absolute lymphocyte count and an increase in mean corpuscular volume. Selumetinib was not associated with apparent clinically significant hematologic changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesNeurofibroma, PlexiformNeurofibromatosis 1Protein Kinase InhibitorsAdolescentChildChild, PreschoolFemaleHumansInfantMaleFollow-Up Studies

Stichwörter der Autor:innen

adverse eventshematologicneurofibromatosis type 1 (NF1)plexiform neurofibromaselumetinib

Substanzen

AZD 6244BenzimidazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Children's National Hospital, Washington, District of Columbia, USA.
  • Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
  • Lurie Children's Hospital, Chicago, Illinois, USA.
  • Riley Children's Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA.

ORCID-Profile: Alan H Siegel, Miriam Bornhorst, Brian D Weiss

Förderung

  • National Institutes of Health (NIH)

Zitieren

APA

Siegel, A. H., Baldwin, A., Heisey, K., Herrera, K., Dufek, A., Patel, H., Kim, A., Bornhorst, M., Weiss, B. D., Blank, P., Fisher, M. J., Widemann, B. C., & Gross, A. M. (2026). Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas. Pediatric Blood & Cancer, 73(9). https://doi.org/10.1002/1545-5017.70477

Vancouver

Siegel AH, Baldwin A, Heisey K, Herrera K, Dufek A, Patel H, et al. Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas. Pediatric Blood & Cancer. 2026;73(9). doi:10.1002/1545-5017.70477

BibTeX
@article{Siegel2026,
  author = {Siegel, Alan H and Baldwin, Andrea and Heisey, Kara and Herrera, Kailey and Dufek, Anne and Patel, Hemaxi and Kim, AeRang and Bornhorst, Miriam and Weiss, Brian D and Blank, Peter de and Fisher, Michael J and Widemann, Brigitte C and Gross, Andrea M},
  title = {Long‐Term Hematologic Effects of Selumetinib Treatment in Children With Neurofibromatosis Type 1‐Associated Plexiform Neurofibromas},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {9},
  doi = {10.1002/1545-5017.70477}
}
Kostenlos starten →